



Patent Docket P3121R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Audrey Goddard et al. Serial No.: 10/700,992 Filed: November 3, 2003 For: Novel Cytokine Receptors and Nucleic Acids Encoding the Same	Group Art Unit: Unknown Examiner: Unknown Customer No.: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Arlington, VA 22313-1450 on April 8, 2004 <u>P. Tobin</u> Patty Tobin
--	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(x) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

0 **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

04/14/2004 BABRAHA1 00000134 070630 10700992

01 FC:1806 180.00 DA

☐ **37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/964,994, filed September 26, 2001 and relied upon in this application for an earlier filing date under 35 USC §120.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "Exhibit A BLAST Results A-1 - A-24" (nucleotide) and "Exhibit B BLAST Results B-1 - B-33)" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of

the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) (Required)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By: 

Bonny G. Yeung, Ph.D.

Reg. No. 53,811

Telephone No. (650) 225-1818

Date: April 8, 2004

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P3121R1C1Serial No.
10/700,992

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Goddard et al.Filing Date
03 Nov 2003

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,179,337	18.12.79	Davis et al.			
	* 2	4,275,149	23.06.81	Litman et al.			
	* 3	4,301,144	17.11.81	Iwashita et al.			
	* 4	4,496,689	29.01.85	Mitra, G.			
	* 5	4,640,835	03.02.87	Shimizu et al.			
	* 6	4,657,760	14.05.87	Kung et al.			
	* 7	4,670,417	02.06.87	Iwasaki et al.			
	* 8	4,676,980	30.06.87	Segal et al.			
	* 9	4,736,866	12.04.88	Leder et al.			
	* 10	4,791,192	13.12.88	Nakagawa et al.			
	* 11	4,816,567	28.03.89	Cabilly et al.			
	* 12	4,870,009	26.09.89	Evans et al.			
	* 13	5,206,344	27.04.93	Katre et al.			
	* 14	5,225,212	06.07.94	Martin et al.			
	* 15	5,364,934	15.11.94	Drayna et al.			
	* 16	5,536,637	16.07.96	Jacobs, K.			
	* 17	5,545,806	13.08.96	Lonberg et al.			
	* 18	5,545,807	13.08.96	Surani et al.			
	* 19	5,569,825	29.10.96	Lonberg et al.			
	* 20	5,625,126	29.04.97	Lonberg et al.			
	* 21	5,633,425	27.05.97	Lonberg et al.			
	* 22	5,654,010	05.08.97	Johnson et al.			
	* 23	5,661,016	26.08.97	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass ²	Translation Yes No	
	* 24	3089	25.07.79	EP (ENGLISH CLAIMS)				
	* 25	404,097	27.12.90	EP (ENGLISH ABSTRACT ATTACHED)				
	* 26	WO 90/13641	15.11.90	PCT				
	* 27	WO 91/00360	10.01.91	PCT				
	* 28	WO 92/20373	26.11.92	PCT				
	* 29	WO 93/08829	13.05.93	PCT				
	* 30	WO 93/11161	10.06.93	PCT				
	* 31	WO 96/07399	14.03.96	PCT				
	* 32	WO 96/27011	06.09.96	PCT				
	* 33	WO 96/40072	19.12.96	PCT				

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992			
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.				
				Filing Date 03 Nov 2003	Group			
FOREIGN PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	* 34	WO 97/03692	06.02.97	PCT				
	* 35	WO 97/33551	18.09.97	PCT				
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)								
	* 36	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)						
	* 37	Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs" <u>Nucleic Acids Research</u> . 25(17):3389-3402 (1997)						
	* 38	Anderson, W.F., "Human Gene Therapy." <u>Science</u> . 256(5058):808-813 (May 8, 1992)						
	* 39	Beal and Dervan, "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation" <u>Science</u> 251:1360-1363 (1991)						
	* 40	BLAST Results A-1 - A-6 (Dayhoff)						
	* 41	BLAST Results B-1 - B-4 (GenBank)						
	* 42	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)						
	* 43	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)						
	* 44	Brennan et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G ₁ fragments" <u>Science</u> 229:81-83 (July 1985)						
	* 45	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)						
	* 46	Caron et al., "Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies." <u>Journal of Experimental Medicine</u> . 176(4):1191-1195 (1992)						
	* 47	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1986)						
	* 48	Chevray and Nathans, "Protein Interaction Cloning in Yeast: Identification of Mammalian Proteins That React With the Leucine Zipper of Jun" <u>Proc. Natl. Acad. Sci. USA</u> 89:5789-5793 (July 1992)						
	* 49	Chien et al., "The Two-Hybrid System: A Method to Identify and Clone Genes for Proteins that Interact with a Protein of Interest." <u>Proc. Natl. Acad. Sci. USA</u> 88:9578-9582 (1991)						
	* 50	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-12 (1976)						
	* 51	Cleland., "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems." <u>Vaccine Design: The Subunit and Adjuvant Approach</u> , Powell and Newman, New York:Plenum Press pps. 439-462 (1995)						
	* 52	Cohen, Jack S. ed. <u>Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression</u> , Boca Raton, FL:CRC Press, Inc. (1989)						
Examiner					Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P3121R1C1Serial No.
10/700,992

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Goddard et al.Filing Date
03 Nov 2003

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 53	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York: Alan R. Liss, Inc. pps. 77-96 (1985)
* 54	Coligan et al. <u>Current Protocols in Immunology</u> , Chapter 5, 1(2) (1991)
* 55	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro" <u>Science</u> 241:456-459 (July 22, 1988)
* 56	Creighton, Thomas E. <u>Proteins: Structures and Molecular Properties</u> , N.Y.: W.H. Freeman & Co. (1983)
* 57	David and Reisfeld., "Protein Iodination with Solid State Lactoperoxidase." <u>Biochemistry</u> 13(5):1014-1021 (1974)
* 58	Dzau et al., "Gene Therapy for Cardiovascular Disease." <u>Trends in Biotechnology</u> . 11:205-210 (1993)
* 59	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular & Cellular Biology</u> 5:3610-3616 (1985)
* 60	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)
* 61	Fields and Song., "A Novel Genetic System to Detect Protein-Protein Interactions." <u>Nature</u> . 340:245-246 (1989)
* 62	Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> . 14(7):845-851 (Jul 1996)
* 63	Gruber et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in <i>Escherichia Coli</i> " <u>Journal of Immunology</u> 152:5368-5374 (1994)
* 64	Holliger et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments." <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)
* 65	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
* 66	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
* 67	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
* 68	Hora et al., "Controlled Release of Interleukin-2 from Biodegradable Microspheres" <u>Bio/Technology</u> 8:755-758 (August 1990)
* 69	Johnson et al., "A month-long effect from a single injection of microencapsulated human growth hormone" <u>Nature Medicine</u> 2(7):795-799 (Jul 1996)
* 70	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." <u>Nature</u> . 321:522-525 (May 29, 1986)
* 71	Klein et al., "Selection for Genes Encoding Secreted Proteins and Receptors" <u>Proc. Natl. Acad. Sci. USA</u> 93(14):7108-7113 (1996)
* 72	Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> . 256:495-497 (August 7, 1975)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 03 Nov 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*	73	Kostelny et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers" <u>Journal of Immunology</u> 148(5):1547-1553 (1992)			
*	74	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)			
*	75	Lee et al., "Complexes Formed by (Pyrimidine) _n (purine) _n DNAs on Lowering the pH are Three-Stranded." <u>Nucl. Acids Res.</u> 6:3073-3091 (1979)			
*	76	Lewis, "Controlled release of bioactive agents from lactide/glycolide polymers" <u>Biodegradable Polymers as Drug Delivery Systems</u> , M. Chasin and R Langer, New York:Marcel Dekker pps. 1-41 (1990)			
*	77	Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." <u>Cell</u> . 69:915-926 (Jun 1992)			
*	78	Lonberg and Huszar., "Human Antibodies From Transgenic Mice" <u>International Reviews of Immunology</u> 13(1):65-93 (1995)			
*	79	Lonberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications" <u>Nature</u> . 368(6474):856-859 (Apr 28, 1994)			
*	80	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)			
*	81	Marasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp 120 single-chain antibody" <u>Proc. Natl. Acad. Sci. USA</u> 90:7889-7893 (1993)			
*	82	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)			
*	83	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)			
*	84	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K ⁺ Channel Currents" <u>Science</u> 255:192-194 (1992)			
*	85	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85(14):2149-2154 (Jul 1963)			
*	86	Milstein and Cuello, "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (Oct 1983)			
*	87	Mordenti et al., "The Use of Interspecies Scaling in Toxicokinetics" <u>Toxicokinetics and New Drug Development</u> , Yacobi et al., eds., New York:Pergamon Press pps. 42-96 (1989)			
*	88	Morrison, S., "Immunology: Success in Specification" <u>Nature</u> . 368(6474):812-813 (Apr 28, 1994)			
*	89	Munson and Rodbard, "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)			
*	90	Neuberger, M., "Generating High-Avidity Human Mabs in Mice" <u>Nature Biotechnology</u> . 14(7):826 (Jul 1996)			
*	91	Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" <u>Protein Engineering</u> . 10(1):1-6 (1997)			
*	92	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P3121R1C1	Serial No. 10/700,992
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 03 Nov 2003	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
* 93	Okano et al., "Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse." <u>J. Neurochemistry</u> . 56(2):560-567 (1991)				
* 94	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)				
* 95	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)				
* 96	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology.</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)				
* 97	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)				
* 98	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)				
* 99	Rossi, J.J., "Making Ribozymes Work in Cells." <u>Current Biology</u> . 4(5):469-471 (1994)				
*100	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)				
*101	Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" <u>Journal of Experimental Medicine</u> 175:217-225 (Jan 1, 1992)				
*102	Shopes, "A Genetically Engineered Human IgG Mutant With Enhanced Cytolytic Activity." <u>Journal of Immunology</u> . 148(9):2918-2922 (1992)				
*103	Skinner et al., "Use of the Glu-Glu-Phe C-Terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins." <u>J. Bio. Chem.</u> 266:14163-14166 (1991)				
*104	Stein and Cohen., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review." <u>Cancer Research</u> 48:2659-2668 (May 15, 1988)				
*105	Stevenson et al., "A Chimeric Antibody With Dual Fc Regions (bisFabFc) Prepared by Manipulations at the IgG Hinge." <u>Anti-Cancer Drug Design</u> . 3(4):219-230 (1989)				
*106	Stewart et al. <u>Solid-Phase Peptide Synthesis</u> , San Francisco, CA:W.H. Freeman Co. (1969)				
*107	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)				
*108	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells." <u>Cell</u> . 51:503-512 (Nov 1987)				
*109	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)				
*110	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)				
*111	Tutt et al., "Trispecific F(ab') ₃ Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells" <u>J. Immunol.</u> 147(1):60-69 (1991)				
*112	van der Krol et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences." <u>Biotechniques</u> . 6(10):958-976 (1988)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

